Key Takeaways CRVS shares jumped 208.8% in a month following positive cohort 4 results from a phase I eczema study.Corvus Pharmaceuticals reported deeper and more durable responses with eight-week dosing versus prior cohorts.CRVS said cohort 4 patients saw a 72% EASI reduction at day 56, with no disease flares or serious events.Shares of Corvus Pharmaceuticals (CRVS) have skyrocketed 208.8% in a month. The massive stock price rally was observed after the company announced positive results from cohort 4 of a ...